Earnings

Foghorn Therapeutics Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $16.072M Beat $5.995M Estimate

Aug 6, 2026 · 07:41 AM ET· updated 1h ago

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 54.55 percent. This is a 64.29 percent increase over losses of $(0.28) per share

Why It Matters

Foghorn Therapeutics lost less money than people expected in the quarter, and made way more sales than predicted. This shows the company is improving and becoming more efficient at running its business.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

FHTX4.98

+0.09 (+1.95%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.